Gene therapy for muscular dystrophy - A review of promising progress

Expert Opinion on Biological Therapy

Volumn 3, Issue 5, 2003, Pages 803-814

  Gregorevic, Paul ^a   Chamberlain, Jeffrey S ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Duchenne; Dystrophin; Gene therapy; Myoblast; Skeletal muscle; Stem cell; Viral vector

Indexed keywords

ADENOVIRUS VECTOR; DYSTROPHIN; GENE PRODUCT; GLYCOPROTEIN; RETROVIRUS VECTOR; UTROPHIN; VIRUS VECTOR;

ADENO ASSOCIATED VIRUS; CELL TRANSPLANTATION; DNA VECTOR; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DUCHENNE MUSCULAR DYSTROPHY; GENE MUTATION; IMMUNOMODULATION; MYOBLAST; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PATHOGENESIS; REVIEW; STEM CELL; STEM CELL TRANSPLANTATION; TRANSCRIPTION REGULATION; TRANSGENE; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

ANIMALS; CELL TRANSPLANTATION; DYSTROPHIN; GENE THERAPY; GENETIC VECTORS; GLYCOPROTEINS; HUMANS; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, DUCHENNE; STEM CELL TRANSPLANTATION; TRANSGENES;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA; UNIDENTIFIED RETROVIRUS;

EID: 0042170127     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/eobt.3.5.803.21236     Document Type: Review

References (92)

1. ERVASTI JM, CAMPBELL KP: A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. J. Cell Biol. (1993) 122:809-823.
2. PETROF BJ, SHRAGER JB, STEDMAN HH, KELLY AM, SWEENEY HL: Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. USA (1993) 90:3710-3714.
3. HOFFMAN EP, BROWN RH JR, KUNKEL LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell (1987) 51:919-928.
4. BRENMAN JE, CHAO DS, XIA H, ALDAPE K, BREDT DS: Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. Cell (1995) 82:743-752.
5. BIES RD, PHELPS SF, CORTEZ MD, ROBERTS R, CASKEY CT, CHAMBERLAIN JS: Human and murine dystrophin mRNA transcripts are differentially expressed during skeletal muscle, heart, and brain development. Nucleic Acids Res. (1992) 20:1725-1731.
6. CHAMBERLAIN JS, BARJOT C, SCOTT J: Packaging cell lines for generating replication-defective and gutted adenoviral vectors. Methods Mol. Med. (2003) 76:153-166.
7. EMERY AEH: Duchenne Muscular Dystrophy, vol #24, Oxford Medical Publications, Oxford (1993).
8. KAPSA R, QUIGLEY A, LYNCH GS et al.: In vivo and in vitro correction of the mdx dystrophin gene nonsense mutation by short-fragment homologous replacement. Hum. Gene Ther. (2001) 12:629-642.
9. BERTONI C, RANDO TA: Dystrophin gene repair in mdx muscle precursor cells in vitro and in vivo mediated by RNA-DNA chimeric oligonucleotides. Hum. Gene Ther. (2002) 13:707-718. Impressive demonstration of the ability to genetically correct a mutation in muscle that leads to DMD.
10. MANN CJ, HONEYMAN K, MCCLOREY G, FLETCHER S, WILTON SD: Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J. Gene Med. (2002) 4:644-654.
11. BARTLETT RJ, STOCKINGER S, DENIS MM et al.: In vivo targeted repair of a point mutation in the canine dystrophin gene by a chimeric RNA/DNA oligonucleotide. Nat. Biotechnol. (2000) 18:615-622. The first demonstration that a MD-causing mutation could be corrected inside of a cell.
12. AARTSMA-RUS A, JANSON AA, KAMAN WE et al.: Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet. (2003) 12:907-914.
13. COX GA, COLE NM, MATSUMURA K et al.: Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. Nature (1993) 364:725-729.
14. LOVE DR, FLINT TJ, MARSDEN RF et al.: Characterization of deletions in the dystrophin gene giving mild phenotypes. Am. J. Med. Genet. (1990) 37:136-142.
15. PHELPS SF, HAUSER MA, COLE NM et al.: Expression of full-length and truncated dystrophin mini-genes in transgenic mdx mice. Hum. Mol. Genet. (1995) 4:1251-1258.
16. CRAWFORD GE, FAULKNER JA, CROSBIE RH, CAMPBELL KP, FROEHNER SC, CHAMBERLAIN JS: Assembly of the dystrophin-associated protein complex does not require the dystrophin COOH-terminal domain. J. Cell Biol. (2000) 150:1399-1410.
17. HARPER SQ, HAUSER MA, DELLORUSSO C et al.: Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. (2002) 8:253-261. Detailed analysis of the structure and function of the dystrophin protein, which led to the development of optimised microdystrophin genes. This work also used AAV vectors to deliver micro-dystrophins to muscles of an animal model for DMD, showing for the first time that a dystrophic pathology could be reversed after it had developed.
18. SAKAMOTO M, YUASA K, YOSHIMURA M et al.: Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene. Biochem. Biophys. Res. Commun. (2002) 293:1265-1272.
19. WATCHKO J, O'DAY T, WANG B et al.: Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum. Gene Ther. (2002) 13:1451-1460. This manuscript showed that micro-dystrophins could correct many of the functional deficits in dystrophic muscle following AAV vector delivery to mdx mice.
20. MATSUMURA K, ERVASTI JM, OHLENDIECK K, KAHL SD, CAMPBELL KP: Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature (1992) 360:588-591.
21. TINSLEY JM, POTTER AC, PHELPS SR, FISHER R, TRICKETT JI, DAVIES KE: Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene. Nature (1996) 384:349-353. Transgenic mdx mice were shown to display an almost complete absence of dystrophic pathology when they expressed moderate levels of a mini-utrophin. This work provides the best evidence to date supporting the concept of using utrophin to compensate for dystrophin gene mutations.
22. DECONINCK N, TINSLEY J, DE BACKER F et al.: Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice. Nat. Med. (1997) 3:1216-1221.
23. PERKINS KJ, BURTON EA, DAVIES KE: The role of basal and myogenic factors in the transcriptional activation of utrophin promoter A: implications for therapeutic up-regulation in Duchenne muscular dystrophy. Nucleic Acids Res. (2001) 29:4843-4850.
24. HAUSER MA, ROBINSON A, HARTIGAN-O'CONNOR D et al.: Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. Mol. Ther. (2000) 2:16-25.
25. WOLFF JA, MALONE RW, WILLIAMS P et al.: Direct gene transfer into mouse muscle in vivo. Science (1990) 247:1465-1468.
26. LU QL, BOU-GHARIOS G, PARTRIDGE TA: Non-viral gene delivery in skeletal muscle: a protein factory. Gene Ther. (2003) 10:131-142. A wide ranging and thorough review of the approaches being taken to develop non-viral methods for gene therapy of the muscular dystrophies.
27. TRIVEDI RA, DICKSON G: Liposome-mediated gene transfer into normal and dystrophin-deficient mouse myoblasts. J. Neurochem. (1995) 64:2230-2238.
28. CAMPEAU P, CHAPDELAINE P, SEIGNEURIN-VENIN S, MASSIE B, TREMBLAY JP: Transfection of large plasmids in primary human myoblasts. Gene Ther. (2001) 8:1387-1394.
29. VILQUIN JT, KENNEL PF, PATURNEAU-JOUAS M et al.: Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies. Gene Ther. (2001) 8:1097-1107.
30. WELLS DJ: Improved gene transfer by direct plasmid injection associated with regeneration in mouse skeletal muscle. FEBS Lett. (1993) 332:179-182.
31. ZELENIN AV, KOLESNIKOV VA, TARASENKO OA et al.: Bacterial beta-galactosidase and human dysrrophin genes are expressed in mouse skeletal muscle fibers after ballistic transfection. FEBS Lett. (1997) 414:319-322.
32. ZHANG G, BUDKER V, WILLIAMSP, SUBBOTIN V, WOLFF JA: Efficient expression of naked DNA delivered intraarterially to limb muscles of nonhuman primates. Hum. Gene Ther. (2001) 12:427-438. An impressive level of gene transfer was obtained in muscles of non-human primates without using viral vectors. This study provides clues as to how systemic delivery of transgenes to muscle might be obtained.
33. MURAKAMI T, NISHI T, KIMURA E et al.: Full-length dystrophin cDNA transfer into skeletal muscle of adult mdx mice by electroporation. Muscle Nerve (2003) 27:237-241.
34. MAH C, FRAITES TJ JR, ZOLOTUKHIN I et al.: Improved method of recombinant AAV2 delivery for systemic targeted gene therapy. Mol. Ther. (2002) 6:106-112.
35. VOLPERS C, THIRION C, BIERMANN V et al.: Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin g-binding domain in the capsid. J. Virol. (2003) 77:2093-2104.
36. DEAS O, ANGEVIN E, CHERBONNIER C et al.: In vivo-targeted gene delivery using antibody-based nonviral vector. Hum. Gene Ther. (2002) 13:1101-1114.
37. MACCOLL G, BUNN C, GOLDSPINK G, BOULOUX P, GORECKI DC: Intramuscular plasmid DNA injection can accelerate autoimmune responses. Gene Ther. (2001) 8:1354-1356.
38. AMALFITANO A, HAUSER MA, HU H, SERRA D, BEGY CR, CHAMBERLAIN JS: Production and characterization of improved adenovirus vectors with the E1, E2b, and E3 genes deleted. J. Virol. (1998) 72:926-933.
39. DELLORUSSO C, SCOTT JM, HARTIGAN-O'CONNOR D et al.: Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proc. Natl. Acad. Sci. USA (2002) 99:12979-12984. This study showed that gutted adenoviral vectors could achieve widespread delivery of full-length dystrophin to muscles of old and young mice, and that functional deficits resulting from MD could be at least partially reversed even in older, dystrophic muscles.
40. SCOTT JM, CHAMBERLAIN JS: Gutted adenoviral vectors for gene transfer to muscle. Methods Mol. Biol. (2003) 219:19-28.
41. BOGDANOVICH S, KRAG TO, BARTON ER et al.: Functional improvement of dystrophic muscle by myostatin blockade. Nature (2002) 420:418-421. These authors showed that neutralising antibodies against myostatin could be used to induce muscle hypertrophy in mdx mouse muscles, leading to a significant improvement in the dystrophic pathology. This works represents the most impressive improvement in muscle function obtained by a non-genetic approach. Myostatin blockage could presumably also be obtained by genetic approaches.
42. BARTON ER, MORRIS L, MUSARO A, ROSENTHAL N, SWEENEY HL: Muscle-specific expression of insulin-like growth Factor I counters muscle decline in mdx mice. J. Cell Biol. (2002) 157:137-148. IGF-1 induces muscle hypertrophy and enhances regeneration of damaged muscle. This study showed that IGF-1 expression in transgenic mice on the mdx background leads to muscle hypertrophy that resulted in improved muscle function.
43. JIANG Z, FEINGOLD E, KOCHANEK S, CLEMENS PR: Systemic delivery of a high-capadty adenoviral vector expressing mouse CTLA4Ig improves skeletal muscle gene therapy. Mol. Ther. (2002) 6:369-376. This study demonstrated the potential for blocking immune responses to gene therapy vectors in muscle by co-delivery of both a therapeutic transgene and an immunomodulatory transgene. Such a delivery was only possible by using gutted adenoviral vectors with an enormous cloning capacity.
44. ROBERTS ML, WELLS DJ, GRAHAM IR et al.: Stable microdystrophin gene transfer using an integrating adeno-retroviral hybrid vector ameliorates the dystrophic pathology in mdx mouse muscle. Hum. Mol. Genet. (2002) 11:1719-1730.
45. YANT SR, EHRHARDT A, MIKKELSEN JG, MEUSE L, PHAM T, KAY MA: Transposition from a gutless adeno-transposon vector stabilizes transgene expression in vivo. Nat. Biotechnol. (2002) 20:999-1005.
46. HARTIGAN-O'CONNOR D, BARJOT C, SALVATORI G, CHAMBERLAIN JS: Generation and growth of gutted adenoviral vectors. Methods Enzymol. (2002) 346:224-246.
47. FLOTTE TR, CARTER BJ: Adeno-associated virus vectors for gene therapy. Gene Ther. (1995) 2:357-362.
48. YUASA K, SAKAMOTO M, MIYAGOE-SUZUKI Y et al.: Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product. Gene Ther. (2002) 9:1576-1588.
49. XIAO X, LI J, SAMULSKI RJ: Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. (1996) 70;8098-8108.
50. RABINOWITZ JE, ROLLING F, LI C et al.: Cross-packaging of a single adeno-associated virus (AAV) Type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J. Virol. (2002) 76:791-801.
51. XIAO W, CHIRMULE N, BERTA SC, MCCULLOUGH B, GAO G, WILSON JM: Gene therapy vectors based on adeno-associated virus Type 1. J. Vitro. (1999) 73:3994-4003.
52. RUTLEDGE EA, HALBERT CL, RUSSELL DW: Infectious dones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV Type 2. J. Virol. (1998) 72:309-319.
53. SCOTT JM, LI S, HARPER SQ et al.: Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscul. Disord. (2002) 12(Suppl. 1):S23-S29.
54. GAO GP, ALVIRA MR, WANG L, CALCEDO R, JOHNSTON J, WILSON JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. USA (2002) 99:11854-11859.
55. DUAN D, YUE Y, ENGELHARDT JF: Dual vector expansion of the recombinant AAV packaging capacity. Methods Mol. Biol. (2003) 219:29-51.
56. DUAN D, YUE Y, YAN Z, ENGELHARDT JF: A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat. Med. (2000) 6:595-598. An impressive demonstration of the ability to deliver gene expression cassettes that exceed the cloning capacity of AAV vectors by taking advantage of the concatamerisation of AAV genomes after cell transduction in order to achieve trans-splicing between, and joining of, the two halves of an expression cassette.
57. STEDMAN H, WILSON JM, FINKE R, KLECKNER AL, MENDELL J: Phase I clinical trial utilizing gene therapy for limb girdle muscular dystrophy: alpha-, beta-, gamma-, or delta-sarcoglycan gene delivered with intramuscular instillations of adeno-associated vectors. Hum. Gene Ther. (2000) 11:777-790.
58. FASSATI A, SERPENTE P, WELLS DJ, WALSH FS, DICKSON G: Retroviral-mediated gene transfer into murine and human skeletal muscle for the correction of dystrophin deficiency. Biochem. Soc. Trans. (1996) 24:275S.
59. SEPPEN J, BARRY SC, HARDER B, OSBORNE WR: Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. Blood (2001) 98:594-596.
60. SAKODA T, KASAHARA N, HAMAMORI Y, KEDES L: A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. J. Mol. Cell Cardiol. (1999) 31:2037-2047.
61. KANG Y, STEIN CS, HETH JA et al.: In vivo gene transfer using a nonprimate lentiviral vector pseudotyped with Ross River Virus glycoproteins. J. Virol. (2002) 76:9378-9388.
62. KAFRI T, BLOMER U, PETERSON DA, GAGE FH, VERMA IM: Sustained expression of genes delivered directly into liver and muscle by lentiviral vectors. Nat. Genet. (1997) 17:314-317.
63. MACKENZIE TC, KOBINGER GP, KOOTSTRA NA et al.: Efficient transduction of liver and muscle after in utero injection of lentiviral vectors with different pseudotypes. Mol. Ther. (2002) 6:349-358. A detailed study of the ability to modify the tropism of lentiviral vectors, which was used to obtain permanent delivery of expression cassettes to muscle and liver. This study suggests a potential route to therapy of MDs that would involve gene transfer in utero.
64. BONCI D, CITTADINI A, LATRONICO MV et al.: 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther. (2003) 10:630-636.
65. TROBRIDGE G, VASSILOPOULOS G, JOSEPHSON N, RUSSELL DW: Gene transfer with foamy virus vectors. Methods Enzymol. (2002) 346:628-648.
66. EMERY DW, YANNAKI E, TUBB J, NISHINO T, LI Q, STAMATOYANNOPOULOS G: Development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma-globin gene silencing in vivo. Blood (2002) 100:2012-2019.
67. HEISTER T, HEID I, ACKERMANN M, FRAEFEL C: Herpes simplex virus Type 1/adeno-associated virus hybrid vectors mediate site-specific integration at the adeno-associated virus preintegration site, AAVS1, on human chromosome 19. J. Virol. (2002) 76:7163-7173.
68. WANG Y, CAMP SM, NIWANO M et al.: Herpes simplex virus Type 1/adeno-associated virus rep(+) hybrid amplicon vector improves the stability of transgene expression in human cells by site-specific integration. J. Virol. (2002) 76:7150-7162.
69. GREELISH JP, SU LT, LANKFORD EB et al.: Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nat. Med. (1999) 5:439-443. The most dramatic example to date of the potential to achieve systemic delivery of a viral vector to widely dispersed muscles throughout the body. The method was used to obtain an impressive amelioration of pathology in a hamster model for limb-girdle MD and provided additional clues to the nature of the pathology.
70. CHO WK, EBIHARA S, NALBANTOGLU J et al.: Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route. Hum. Gene Ther. (2000) 11:701-714.
71. CARLSON BM, FAULKNER JA: The regeneration of skeletal muscle fibers following injury: a review. Med. Sci. Sports Exerc. (1983) 15:187-198.
72. KARPATI G, POULIOT Y, ZUBRZYCKA-GAARN E et al.: Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation. Am. J. Pathol. (1989) 135:27-32.
73. PARTRIDGE TA, MORGAN JE, COULTON GR, HOFFMAN EP, KUNKEL LM: Conversion of mdx myofibres from dystrophin-negative to - positive by injection of normal myoblasts. Nature (1989) 337:176-179.
74. MOISSET PA, GAGNON Y, KARPATI G, TREMBLAY JP: Expression of human dystrophin following the transplantation of genetically modified mdx myoblasts. Gene Ther. (1998) 5:1340-1346.
75. FLOYD SS JR, CLEMENS PR, ONTELL MR et al.: Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. Gene Ther. (1998) 5:19-30.
76. PARTRIDGE T: Myoblast transplantation. Neuromuscul. Disord. (2002) 12(Suppl. 1):S3-S6.
77. HODGETTS SI, SPENCER MJ, GROUNDS MD: A role for natural killer cells in the rapid death of cultured donor myoblasts after transplantation. Transplantation (2003) 75:863-871.
78. HODGETTS SI, BEILHARZ MW, SCALZO AA, GROUNDS MD: Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. Cell Transplant. (2000) 9:489-502.
79. WEBSTER C, BLAU HM: Accelerated age-related decline in replicative life-span of Duchenne muscular dystrophy myoblasts: implications for cell and gene therapy. Somat. Cell Mol. Genet. (1990) 16:557-565.
80. LATTANZI L, SALVATORI G, COLETTA M et al.: High efficiency myogenic conversion of human fibroblasts by adenoviral vector-mediated MyoD gene transfer. An alternative strategy for ex vivo gene therapy of primary myopathies, J. Clin. Invest. (1998) 101:2119-2128.
81. FASSATI A, WELLS DJ, SGRO SERPENTE PA et al.: Genetic correction of dystrophin deficiency and skeletal muscle remodeling in adult mdx mouse via transplantation of retroviral producer cells. J. Clin. Invest. (1997) 100:620-628.
82. HUARD C, MOISSET PA, DICAIRE A et al.: Transplantation of dermal fibroblasts expressing MyoD1 in mouse muscles. Biochem. Biophys. Res. Commun. (1998) 248:648-654.
83. MINASI MG, RIMINUCCI M, DE ANGELIS L et al.: The mesoangioblast: a multipotent, self-renewing cell that originates from the dorsal aorta and differentiates into most mesodermal tissues. Development (2002) 129:2773-2783.
84. QU-PETERSEN Z, DEASY B, JANKOWSKI R et al.: Identification of a novel population of muscle stem cells in mice: potential for muscle regeneration. J. Cell Biol. (2002) 157:851-864.
85. DE BARI C, DELL'ACCIO F, VANDENABEELE F, VERMEESCH JR, RAYMACKERS JM, LUYTEN FP: Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane. J. Cell Biol. (2003) 160:909-918.
86. ZUK PA, ZHU M, ASHJIAN P et al.: Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell (2002) 13:4279-4295.
87. ASAKURA A, SEALE P, GIRGIS-GABARDO A, RUDNICKI MA: Myogenic specification of side population cells in skeletal muscle. J. Cell Biol. (2002) 159:123-134. The most detailed and thorough manuscript on the relationship between muscle precursor cells and stem cells resident in haematopoietic and muscle tissues. This study introduces important concepts relevant to the development of ex vivo therapy for muscle diseases.
88. TORRENTE Y, TREMBLAY JP, PISATI F et al.: Intraarterial injection of muscle-derived CD34(+)Sca-1(+) stem cells restores dystrophin in mdx mice. J. Cell Biol. (2001) 152:335-348.
89. GALLI R, BORELLO U, GRITTI A et al.: Skeletal myogenic potential of human and mouse neural stem cells. Nat. Neurosci. (2000) 3:986-991.
90. PARTRIDGE TA: Stem cell route to neuromuscular therapies. Muscle Nerve (2003) 27:133-141.
91. SMYTHE GM, GROUNDS MD: Exposure to tissue culture conditions can adversely affect myoblast behaviour in vivo in whole muscle grafts: implications for myoblast transfer therapy. Cell Transplant. (2000) 9:379-393.
92. SOMMER B, RINSCH C, PAYEN E et al.: Long-term doxycycline-regulated secretion of erythropoietin by encapsulated myoblasts. Mol. Ther. (2002) 6:155-161.